Cardiovascular Systems Names Kevin J. Kenny Executive Vice President of Sales and Marketing
May 09 2011 - 4:15PM
Business Wire
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) has named
Kevin J. Kenny executive vice president of sales and marketing, a
new position, effective today. Kenny will oversee all sales and
marketing functions with the goal of building on the marketplace
success CSI has achieved since its first-generation Diamondback
360° product was launched in late 2007.
“Kevin has extensive executive experience in sales and
marketing, managing large commercial organizations and delivering
results in both market growth and share,” said David L. Martin,
president and chief executive officer for Cardiovascular Systems.
“We’re excited to have him play a leading role in commercializing
our new Stealth 360°TM Orbital PAD System and driving physician
adoption of our technology as the front-line treatment for
peripheral arterial disease. We have established scientific proof
of our orbital PAD systems’ utility, and we are introducing an
easy-to-use product with the Stealth 360°. Adding Kevin to our team
at this stage will raise CSI to a new level of growth and
leadership in the vascular intervention market.”
Kenny brings more than 20 years of leadership experience to CSI.
Prior to CSI, he held several positions at Medtronic, most recently
executive consultant-special projects for Medtronic Spine and
Biologics, and prior to that, vice president of U.S. sales for that
division, which is Medtronic’s second-largest division. Kenny
joined the Spine and Biologics division in 2002 and held regional
and national sales positions with increasing responsibilities.
Earlier, Kenny served as vice president of U.S. sales for Bausch
and Lomb, as well as various sales leadership roles with
B.Braun/McGaw. Kenny received a bachelor’s degree in business
administration from California State University in Sacramento.
Kenny added, “I look forward to leveraging my medical device
industry experience to position CSI for accelerated growth. I am
excited about CSI’s products, commitment to innovation and
research, and growth prospects.”
About Cardiovascular Systems, Inc.Cardiovascular Systems,
Inc., based in St. Paul, Minn., is a medical device company focused
on developing and commercializing innovative solutions for treating
vascular and coronary disease. The company’s Stealth 360°™,
Diamondback 360® and Diamondback Predator 360® Orbital PAD Systems
treat calcified and fibrotic plaque in arterial vessels throughout
the leg in a few minutes of treatment time, and address many of the
limitations associated with existing surgical, catheter and
pharmacological treatment alternatives. The U.S. FDA granted 510(k)
clearance for the use of the Diamondback 360° in August 2007 and
for the Stealth 360° in March 2011. To date, more than 46,000 PAD
procedures have been performed using the Diamondback 360° in
leading institutions across the United States.
CSI has also commenced its ORBIT II Investigational Device
Exemption clinical trial to evaluate the safety and effectiveness
of its Diamondback 360° System in treating coronary arteries. The
coronary system is under clinical investigation and is currently
not commercially available in the United States.
For more information, visit the company’s website at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024